Thermo Fisher Scientific (USA), a multinational biotechnology product development company, and the University of Pittsburgh (USA) have established a new Pharmacogenomics (PGx) Center of Excellence that combines expertise and technology in genomics, bioinformatics, implementation science, medication response phenotyping and education.
Pharmacogenomics (PGx) is the study of how genes affect a person’s response to medications. PGx combines the study of how medications affect our bodies (pharmacology) with the study of our genes and their functions (genomics) to identify effective, safe medications and doses for patients.
The Center aims to discover and validate medication response predictors in patients, overcome clinical implementation barriers and demonstrate the value of pre-emptive PGx testing in routine clinical practice.
Strategically, the PGx Center of Excellence will focus on:
- State-of-the-art technologies to identify the genomic determinants of medication response and provide world-class PGx analysis and interpretation for researchers, clinicians and patients;
- Demonstrating the clinical utility and economic value of PGx-based care in emerging healthcare delivery models at Pitt/UPMC, the largest nonprofit academic health system in the nation;
- Developing effective methods for return of PGx results to achieve clinician and patient education;
- Advancing PGx and technology awareness and adoption, providing leadership in technology translation through innovative educational platforms, conferences and hands-on workshops hosted by Pitt and Thermo Fisher to disseminate expertise and best practices nationally.
The new Center will immediately leverage Pitt+Me Discovery, the new institutional bio-repository developed by the University of Pittsburgh Clinical and Translational Science Institute (CTSI). It also extends the highly successful PGx clinical implementation (PreCISE-Rx) and (Test2Learn) educational programs already implemented in Pittsburgh.